Trending...
- Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
- Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
- Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
- New from Regal House Publishing, The Meaning of Fear, a psychological crime drama
- New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
- Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
0 Comments
Latest on ncarol.com
- Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
- North Carolina Leadership Strategist Brings Real-World Solution
- Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
- SoPi Rugby's Taco Cook-Off (Cinco de Mayo Weekend)
- Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
- Healing Hearts Home Care Hosts Peace of Mind Community Event
- AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
- CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
- Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
- Hinton Called for Maternal Instincts in AI; They're Ready for Testing with Anthropic's Mythos
- Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
- Charlotte Founder Launches Foot Odor Brand After Years of Embarrassment
- Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
- New from Regal House Publishing, Local Heroes, Lyric poems exploring themes drawn from ordinary life
- New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
- Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
- Five-star Review for Berklee School of Music Textbook
- ZionSphere Launches Multi-Platform Virtual Reality Faith Experience Built from Rocky Mount, NC
- Rocky Mount Founder Builds Virtual Reality Bible Experiences After Receiving Divine Directive
- Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing